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SUM M ARY
In tumour development, proteases such as plasminogen activators (PAs) play a role in degradation of the 
extracellular matrix and other tissue barriers. Recently, we dem onstrated that plasminogen activators, their 
inhibitors, and urokinase receptor emerge in late stages of cutaneous melanocytic tum our progression. In this study 
we investigated the expression and distribution of the various components o f the PA  system and the presence of PA  
enzyme activity in 45 freshly frozen primary uveal melanomas with known follow-up (14 spindle and 31 non-spindle 
type) and in métastasés (« = 5). Tissue-type PA (t-PA) was found in endothelium of blood vessels and in tum our cells 
in almost all lesions, and was markedly present at the invasive front (towards the sclera and Bruch’s membrane), but 
no correlation with tumour-related death could be established. Urokinase PA (u-PA) was expressed focally, by only 
five non-spindle cell melanomas but in all métastasés. u-PA expression correlated with occurrence of metastasis* 
u-PA receptor (u-PAR) was present in one-third o f all the tum ours examined* Plasminogen activator inhibitors 
(PAI-1 and PAI-2) were found only focally in approximately 10 per cent o f the lesions. Staining o f t-PA, u-PA, and 
PAI was observed in all the métastasés. We conclude that in uveal melanoma, u-PA expression may be associated 
with metastatic disease and accordingly with a poor prognosis. Further research on a larger group o f tumours with 
known follow-up is needed to establish whether u-PA positivity is of additional prognostic value in uveal melanoma.
key  w o r d s —Uveal melanoma, plasminogen activation, proteolysis, immunohistochemistry, urokinase.
INTRODUCTION
To migrate from the primary tum our into blood 
vessels and to home and grow at a distant site in 
the body, tumour cells need an extensive repertoire 
of proteins.1 For migration through and break­
down of tissue barriers, proteases are required.2 
An important proteolytic system involved in 
tumour progression comprises the proteins of the
Addressee for correspondence: Teun de Vries, Department 
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plasminogen activator system.3,4 The two known 
plasminogen activators (PAs) are tissue-type 
(t-PA) and urokinase-type plasminogen activator 
(u-PA). PA activity can be inhibited by specific PA 
inhibitors, PAI-1 and PAI-2.5 u-PA activity can 
be focused at the cell surface by binding to its 
receptor (u-PAR). Also, u-PA activity can be 
enhanced by binding to the receptor, as the con­
version of the inactive pro-u-PA to active u-PA 
is facilitated on the cell surface.6,7 Furtherm ore, 
by rapid internalization of u-PAR saturated 
with u-PA:PAI-l and recycling of u-PAR, the 
availability o f u-PAR for u-PA binding is
CCC 0022-3417/95/010059-09 
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ensured.8“10 The saturation of the u-PAR is either 
autocrine or paracrine.11-13
The actual involvement of PAs in tumour cell 
migration and metastasis formation has been 
shown in several model systems.14“16 Elevated 
levels of u-PA, u-PAR, and PAI in human malig­
nant tumour tissue relative to the benign precursor 
lesion or normal tissue have been reported for 
tumours of diverse origin.17-22 Furthermore, u-PA 
content has been shown to be a valuable prognos­
tic marker for mammary carcinoma.19,23 The role 
of t-PA in tumour progression, however, is more 
ambiguous. Lower levels of t-PA in tumours com­
pared to benign lesions have been reported for 
tumours of the mammary gland24 and the ovary.21 
Regarding cutaneous melanoma, some reports 
indicate a high expression of t-PA in melanoma 
cell lines16, 5,26 and cutaneous melanoma 
lesions.25,26,39
We recently demonstrated, both in a nude 
mouse model and in fresh human cutaneous 
melanocytic lesions,22 a possible role for the PA 
system in melanoma tumour progression. u-PA 
and PAI expression was related to a high meta­
static potential of melanoma cell lines in nude 
mice.1 This was reflected in the in vivo situation 
in fresh human melanocytic lesions: u-PA, PAI-1 
and PAI-2, but also t-PA and u-PAR emerge 
in late stages of cutaneous melanocytic tumour 
progression.22
In this study, we extended our investigation 011 
the involvement of the PA system in melanoma 
tumour progression to melanoma of the uvea. 
Melanoma of the uvea is the most common pri­
mary intraocular malignancy in adults27 and 
several factors have been found to influence the 
prognosis. These include tumour cell type (spindle 
cell type has a better prognosis than non-spindle 
cell type) and tumour diameter. Uveal melanomas 
differ from cutaneous melanomas in several 
aspects. Uveal melanomas spread haemato- 
genously, preferentially to the liver, whereas 
cutaneous melanomas primarily metastasize by 
lymphatics. The estimated 5-year survival rate for 
uveal melanoma is 75 per cent28 and is comparable 
to that for cutaneous melanoma.29 The aim of this 
study was to investigate the expression of the 
different components o f the PA system in uveal 
melanoma. The presence of these proteins 
was studied on fresh human lesions of primary 
uveal melanoma and metastases of uveal mela­
noma using immunohistochemistry and in situ 
zymography.
MATERIALS AND METHODS
Tissue specimens
Specimens from primary uveal melanomas were 
obtained from 45 patients treated at the Depart­
ment of Ophthalmology, Erasmus University, 
Rotterdam, The Netherlands between 1987 and 
1992. The enucleated eyes were transported on 
melting ice to the Department of Pathology. After 
transillumination, the eyes were cross-sectioned 
through the tum our and part of the tumour was 
snap-frozen in OCT compound (Tissue-tek) and 
stored at — 70°C. The remainder of the eye was 
fixed in formalin and embedded in paraffin.
Five uveal melanoma metastases were obtained 
from three patients with skin («= 2), heart (n -  2), 
and liver (n=1) metastases. From four metastases, 
no primary tum our was available. From one 
metastasis, the primary tumour was also included 
in this study. Metastatic tumours were obtained 
from the Departments of Pathology of Nijmegen 
( n - 4) and Rotterdam  (ft=l).
Antibodies
Rabbit anti-human t-PA and u-PA polyclonal 
antibodies were from the Gaubius Institute, 
Leiden, The Netherlands and have been used in 
earlier studies.16,22 Monoclonal antibodies against 
human u-PAR (# 3936) and human PAI-1 (# 380) 
were purchased from American Diagnostica Inc., 
Greenwich CT, USA. The rabbit and goat poly­
clonal antibodies against human PAI-2 were a 
generous gift from E. Schüler, Behring Werke AG, 
Marburg, Germany. All antibodies against compo­
nents of the PA system were used in a previous 
study.22 In that study, using parallel sections for 
m RNA in situ hybridization, we established with 
these antibodies that cells producing the mRNA 
also contained the protein. Detection of the 
melanocytic differentiation marker gp-100 with 
monoclonal antibody NKI-beteb30 was used to 
establish the melanocytic origin of the tumours.
Immunohistochemistry
For immunohistochemistry, 4 jim cryostat sec­
tions were air-dried overnight at room temperature 
and stored at — 80°C until use. Dilutions of the 
antibodies and staining procedure were as used 
before.22 Stainings with monoclonal antibodies 
were developed with an ABC technique, and those 
with polyclonal antibodies with peroxidase
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labelled anti-rabbit or anti-goat secondary anti­
body. Bound antibodies were visualized by using 
3-amino-9-ethylcarbazole as a substrate for per­
oxidase. After counterstaining the nuclei with 
Papanicolaou4 s Harris solution, sections 
were mounted with Kaisers glycerin (Merck, 
Darmstadt, Germany). A lymph node metastasis 
from a cutaneous melanoma, previously found to 
express abundant u-PA, u-PAR and PAI-1 p ro ­
tein, was used as a positive control; for t-PA, the 
staining of blood vessels served as an internal 
control, and for PAI-2, staining o f sections from 
fresh human placenta served as a positive control. 
An incubation in which the first antibody was 
omitted served as a negative control.
Score
For each section, the percentage o f positively 
labelled melanocytic cells was estimated. Each 
section was assigned to one o f the following cat­
egories: 0 per cent, 1-5 per cent, 5-25 per cent and 
25-100 per cent positivity. Notes were taken o f 
other staining components (fibroblast-like cells, 
extracellular matrix) among the melanocytic 
areas. Sections were scored independently by two 
observers (CMM, MRvB). Discrepancies were 
found in only a few cases. These cases were 
re-evaluated jointly until agreement was reached.
In situ zymography
The technique has been described in great detail 
by Sappino et a/.31 and De Vries et a i 22 Briefly, 
8 jim cryostat sections were covered with an over­
lay mixture containing dry milk, plasminogen, and 
agar. At spots where plasminogen activation 
occurs, lysis of the gel takes place, making the gel 
transluminant. Addition to the gel o f polyclonal 
antibodies against t-PA or u-PA allows discrimi­
nation between the two plasminogen activators. In 
addition, amiloride also inhibits u-PA specifically. 
With each incubation session, xenograft lesions of 
the human melanoma cell lines BLM or MV3, 
known to express abundant u-PA and hardly any 
t-PA,16 were included as a positive control.
RESULTS
Clinico-pathological data
A histopathological diagnosis was obtained on 
paraffin-embedded tissues. The cell type of' the
tum ours was classified as follows, using the pres­
ence or absence of any epithelioid cells as the 
criterion: spindle («=14, tumours containing only 
spindle cells) or non-spindle (n=31, a combination 
of mixed and purely epithelioid tumours).32 The 
other variables that we measured included greatest 
tum our diameter, tumour height, the presence of 
episcleral growth, and the presence of vascular 
invasion. All but two specimens examined con­
tained more than 50 per cent viable tumour cells.
Follow-up was available in all patients included 
in this study; from one of these patients, a freshly 
frozen subcutaneous mestatatic lesion was 
obtained. Eight out of 45 patients died from 
tumour-related death (TRD); three died of other 
causes. The total mean follow-up was 34*7 months.
In ten eyes, extrascleral growth was noted; three 
melanomas showed obvious vascular invasion.
Jm mun o h istoch em is try
All primary tumours and metastases stained 
with NKI-beteb,30 recognizing gp-100, a melano­
cytic differentiation marker (not shown).
Tissue sections were stained for t-PA, u-PA, 
u-PAR, PAI-1 and PAI-2. Typical examples of 
immunohistochemical staining are shown in Fig. 1. 
The total number of lesions which stained for the 
different components is summarized in Table I. In 
Fig, 2, the percentage of stained melanocytic cells 
per cell type of uveal melanoma is displayed.
t-PA
In all lesions, abundant t-PA immunoreactivity 
was found in the wall of blood vessels (Fig. la). 
The correlation between t-PA expression and cell 
type is shown in Fig. 2: 42 out o f  45 tumours 
contained t-PA; however, a moderate to abundant 
staining (>5 per cent tumour cells, n —16) was seen 
predominantly for non-spindle cell type tumours 
(14/16). Interestingly, in four tumours t-PA 
staining was strikingly in nests o f pleomorphic 
epithelioid cells. These cells were located around 
the vessels at both invasive fronts, i.e., towards the 
sclera (Fig. lb) and towards Bruch’s membrane 
(Fig. lc). There was no relationship between the 
percentage of t-PA positivity and TRD. All 
metastases contained t-PA.
u-PA and u-PAR
While no u-PA expression could be detected in 
any of the spindle cell-type tumours tested, focal
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u-PA staining (<5 per cent) of tumour cells as well 
as staining o f fibroblast-like cells was detected in 
five non-spindle cell tumours. In two cases, u-PA 
expression correlated with TRD; one patient was 
known to have metastases, and for two patients 
follow-up was short (32 and 18 months). All five 
metastases expressed u-PA protein (Fig. Id).
Focal u-PAR immunoreactivity (<5 per cent) 
was seen in 15 tumours; 11 out of 15 were non­
spindle cell tumours. Both tumour cells (Fig. le) 
and stromal cells showed a cytoplasmic staining 
aspect. Two metastases contained u-PAR.
PAI-1 and PA 1-2
PAI-1 protein was observed in only six primary 
tumours (three were of the spindle cell type), but in 
the majority of metastatic tumours (four out of 
five). The localization was in tumour cells and in 
the extracellular matrix (Fig. If).
PAI-2 protein was observed in 5 out of 45 
tumours and was found only in lesions of the 
non-spindle cell type. PAI-2 was expressed both by 
tumour cells and by fibroblast-like cells (Fig. lg). 
One metastasis contained PAI-2.
In two out of five u-PA-positive tumours, 
u-PAR and PAI were found in the same lesion, 
both patients died from metastatic disease. One of 
these two patients showed expression of all five 
components. A trend towards higher expression 
(higher percentage of immunoreactive cells) and a 
higher percentage of positive lesions in non-spindle 
compared to spindle cell lesions for t-PA, u-PA, 
u-PAR, and PAI-2 can be deduced from Fig. 2.
In situ zymography
In situ zymography was performed on sections 
of all lesions studied. In all cases, t-PA activity was 
found, often in a dotted pattern (Fig. 3, first row). 
By comparing the lysis pattern with the haema- 
toxylin and eosin-stained sections, we could assign 
t-PA activity to blood vessels. Lysis in tumours 
with t-PA immunoreactivity in the highest cat-
Table I—Immunohis to chemical staining of the compo­
nents of the plasminogen activation system in primary 
uveal melanomas and in metastases of uveal melanoma
t* s e Total
Primary uveal melanoma (nz--45)
*
Spindle («=14)
t-PA 13 3 3 13
u-PA 0 0 0 0
u-PAR 3 1 0 3
PAI-1 2 2 1 3
PAI-2 0 0 0 0
Non-spindle («= 31)
t-PA 29 16 5 29
u-PA 5 2 0 5
u-PAR 12 5 0 14
PAI-1 1 3 2 3
PAI-2 5 3 1 5
Metastases o f uveal melanoma (n=5)
t-PA 4 1 3 5
u-PA 5 4 1 5
u-PAR 2 0 0 2
PAI-1 3 1 1 4
PAI-2 0 1 0 1
*t=Staining of tumour cells; s=stromal cells; e=extracellular 
matrix stained in these lesions.
egory (25-100 per cent) occurred faster and was 
more generalized throughout the section (compare 
Fig. 3, first and second row). Also in a few 
metastases we could detect t-PA activity in an area 
with mainly tumour cells (Fig. 3, third row). 
Except for the positive control BLM and MV3 
xenografts (Figure 3, fourth row), u-PA activity 
could not be detected in any of the tumours 
studied.
DISCUSSION
We recently studied the involvement of plas­
minogen activation in melanoma tumour pro­
gression, both in a nude mouse system and in 
the in vivo situation on sections of fresh human
Fig. 1—Immunohistochemical staining of components of the plasminogen activator system in fresh human uveal melanoma 
lesions. Typical staining examples in primary lesions (a-c, e-g) and a metastasis (d) are shown, (a) t-PA protein in blood vessels, 
(b) t-PA present in tumour cells at the scleral (Sc) invasive front (arrow-head shows a nerve). t-PA present in tumour cells adjacent 
to the retinal pigment epithelium where Bruch’s membrane (Br) is ruptured (rupture not seen), (d) u-PA is present in tumour cells 
in this metastasic lesion, (e) u-PAR is located at the invasive front towards the sclera in this lesion, (f) Network like PAI-1 
distribution in the extracellular matrix surrounding tumour cells, (g) PAI-2 was found focally in the stroma and in tumour cells (not 
shown). Cell types: spindle cell tumours (a) and non-spindle cell tumours (b-c, e-g)
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Fig. 2—Percentage of immunohistochemically stained tumour cells and percentage of immunoreactive lesions including staining of 
extracellular matrix and stroma cells (e and s in Table I), expressed as a percentage of the total number of lesions. Fourteen 
tumours had purely spindle cell type (spindle) morphology and 31 tumours (either of mixed origin or purely epithelioid) contained 
epithelioid ceils (non-spindle). In non-spindle cell melanomas, a higher percentage of positive lesions and higher percentages of 
positive cells were observed for t-PA, u-PA, u-PAR, and PAI-2. Metastases are excluded from this diagram due to the low numbers 
included in this study. See also Table I
cutaneous melanocytic lesions. u-PA, PAI-1, and 
PAI-2 expression in human melanoma cell lines 
correlated with a high metastatic capacity in nude 
mice. All cell lines contained t-PA and u-PAR.16 In 
human cutaneous melanocytic lesions, u-PA, 
PAI-1, and PAI-2 but also t-PA and u-PAR, were 
found in the most malignant lesions only 
(advanced primary melanomas and melanoma 
metastases). Here, we extended our study on the 
involvement of the plasminogen activation system 
in melanocytic lesions to uveal melanoma. Once 
the diagnosis of metastatic disease in uveal mela­
noma is made (usually by fine needle aspiration), 
the subsequent median survival is only 2-4 
months.33,34 Therefore metastatic tissue is hard to 
access and only five metastases were available.
Little is known concerning the presence of pro­
teases in uveal melanoma lesions. The involvement 
of proteases in metastatic spread of uveal mela­
noma has recently been suggested by Cottam 
ei al.,35 who detected the 72 and 92 kD type IV 
collagenase in the culture medium of 15 primary 
cultures of uveal melanoma. Furthermore, t-PA 
activity in supernatants of primary cultures of 
uveal melanoma seemed to correlate with scleral
invasion in the tumour lesion, whereas no u-PA 
activity could be detected.36 Interestingly, the 
choroid itself expresses t-PA37 and u-PA.
In our study, t-PA protein was expressed by 
tumour cells in the vast majority of the lesions. 
Expression of t-PA in uveal melanoma therefore 
does not differ from previous reports on melanoma 
as a source for t-PA: abundant t-PA was found in 
melanoma cell lines16,26,27 and in cutaneous mel­
anocytic lesions.26 t-PA was expressed in a larger 
percentage of the tumour cells in non-spindle cell 
tumours. Immunoreactive cells often had a 
perivascular localization. The localization of t-PA- 
positive cells at both the scleral and Bruch’s 
membrane invasion front was remarkable. This
4
observation is in agreement with the work of 
Cottam et al.,36 who found that elevated t-PA 
activity in primary cultures of uveal melanoma 
correlated with scleral invasion. t-PA posi- 
tivity was noted in varying percentage (0 per cent 
up to 25-100 per cent categories) in patients 
who had died from TRD as well as in patients 
which were still alive. No relationship between 
the extent of t-PA positivity and TRD could be 
established.
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Fig. 3—In situ zymography on fresh uveal melanocytic lesions, Plasminogen activation 
was t-PA mediated in all cases studied and located in blood vessels and in tumour cells. 
Examples are shown of three cases, One non-spindle uveal melanoma had t-PA 
immunoreactivity in blood vessels but not in tumour cells (first row). One non-spindle 
uveal melanoma where 5-25 per cent of the tumour cells stained for t-PA in 
immunohistochemistry is shown (second row); note that lysis is more abundant at the 
sclera site (arrow), Also, a metastasis of uveal melanoma (third row) showed more 
generalized t-PA mediated lysis. A u-PA positive MV3 xenograft, where t-PA mediated 
lysis had not yet occurred, is included (fourth row), Columns: neg. control: casein layer 
without plasminogen; u-PA+t-PA: casein layer with addition of plasminogen; t-PA: 
casein layer+plasminogen + polyclonal antibody against u-PA; u-PA: casein 
layer+ plasminogen+ polyclonal antibody against t-PA, Incubation times at 37°C: 5 h 
in all uveal melanoma cases (top three rows) and 1 h (fourth row).
u-PA expression was found focally in only five 
primary uveal melanomas, all of which were of the 
non-spindle type. In two cases, u-PA expression 
correlated with TRD; one patient was known to 
have metastases; and for two patients, follow-up 
was relatively short. All metastases contained 
u-PA-positive cells. Therefore, a clear association 
with progression of disease exists, as could be 
found for some other types of tumours,17,19“21 
including cutaneous melanoma.22 u-PA positivity 
might be an additional prognostic marker for 
uveal melanoma. Nevertheless, six cases with 
TRD did not display u-PA positivity. There­
fore, although a relation between u-PA 
positivity and progression of disease could be
demonstrated in this study, a m ore extensive 
study has to be performed to determine whether 
u-PA is a valuable prognostic m arker for uveal 
melanoma.
W ith in situ zymography, we were able to detect 
only t-PA (both blood vessel and tum our cell 
associated) and no u-PA activity, which is in agree­
ment with findings in primary cultures o f uveal 
melanoma.36 Apparently, the u-PA detected by 
immunohistochemistry is either of the inactive pro­
form  or inactivated by PAL This view is supported 
by the fact that the staining was only cytoplasmic, 
where u-PA is normally in the inactive form. Also, 
the in situ zymography with regional sensitivity 
rather than cellular sensitivity m ight be too
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insensitive to detect less than the 5 per cent 
scattered u-PA positive cells in the tumour.
The expression of u-PAR in many more 
tumours than u-PA is remarkable, though it is in 
agreement with our earlier findings in human 
melanoma cell lines,16 where all cell lines, including 
the non-metastatic ones, expressed u-PAR. u-PAR 
was found in the cytoplasm, indicating that at least 
a portion of u-PAR was not available for binding 
to pro-u-PA.10 Receptor bound pro-u-PA is more 
efficiently converted to active u-PA.6“12
For t-PA, u-PA, u-PAR and PAI-2, a higher 
expression (higher percentage of staining as well as 
a higher number of lesions involved) was found in 
the non-spindle cell uveal melanomas (Fig. 2) as 
compared with the spindle cell melanomas which 
have a better prognosis. These observations and 
the fact that these components were also fre­
quently detected in métastasés implicate the plas­
minogen activation system in the progression of 
disease. Surprisingly, although four out of five 
métastasés were positive, in primary tumours this 
tendency could not be established for PAI-1, which 
is a prognostic marker for mammary carcinoma.18
By comparing the involvement of the PA system 
in uveal and cutaneous melanoma,22 the following 
differences are noteworthy: (1) Using the same 
polyclonal antibody, t-PA was found in almost all 
primary and metastatic lesions of uveal melanoma, 
whereas in cutaneous melanoma, only a few 
métastasés contained t-PA-positive tumour cells. 
(2) In cutaneous melanoma, lesions expressing 
u-PA also expressed u-PA’s regulators u-PAR and 
PAI. For uveal melanoma, this co-expression was 
not as profound (Fig. 2). (3) Uveal melanomas 
expressed u-PA, PAI-1 and PAI-2 in approxi­
mately 10 per cent of the lesions, whereas in 
cutaneous melanoma approximately 60 per cent 
of the thicker primary lesions were positive. In 
addition, fewer tumour cells stained in uveal 
immunoreactive lesions (all u-PA-, PAI-1- and 
PAI-2 positive lesions were scored in the 1-5 per 
cent category). As in cutaneous melanoma, u-PA is 
associated with progression of disease in uveal 
melanoma, but in uveal melanoma, other proteo­
lytic systems could be of more importance in 
metastatic spread, by comparison with cutaneous 
melanoma.
From our study, we conclude that in uveal 
melanoma, u-PA expression may be associated 
with metastatic disease and accordingly with a 
poor prognosis. In our opinion, it would be worth­
while to extend research on the presence of u-PA in
uveal melanoma to a large group of tumours with 
accurate follow-up. In this way, it could be estab­
lished whether u-PA positivity is of additional 
prognostic value in uveal melanoma.
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